Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 6097647, 11 pages
https://doi.org/10.1155/2017/6097647
Research Article

Hidden IgG Antibodies to the Tumor-Associated Thomsen-Friedenreich Antigen in Gastric Cancer Patients: Lectin Reactivity, Avidity, and Clinical Relevance

Department of Oncology and Immunology, National Institute for Health Development, Hiiu 42, 11619 Tallinn, Estonia

Correspondence should be addressed to Kersti Klaamas; ee.iat@samaalk.itsrek

Received 26 July 2016; Accepted 4 January 2017; Published 21 February 2017

Academic Editor: Franco M. Buonaguro

Copyright © 2017 Oleg Kurtenkov and Kersti Klaamas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. F. Springer, “T and Tn, general carcinoma autoantigens,” Science, vol. 224, no. 4654, pp. 1198–1206, 1984. View at Publisher · View at Google Scholar · View at Scopus
  2. G. F. Springer, P. R. Desai, M. Ghazizadeh, and H. Tegtmeyer, “T/Tn pancarcinoma autoantigens: fundamental diagnostic, and prognostic aspects,” Cancer Detection and Prevention, vol. 19, no. 2, pp. 173–182, 1995. View at Google Scholar · View at Scopus
  3. S. Hakomori, “Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens,” Advances in Cancer Research, vol. 52, pp. 257–331, 1989. View at Publisher · View at Google Scholar · View at Scopus
  4. L.-G. Yu, “The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression,” Glycoconjugate Journal, vol. 24, no. 8, pp. 411–420, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. U. Karsten and S. Goletz, “What makes cancer stem cell markers different?” SpringerPlus, vol. 2, no. 1, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. W.-M. Lin, U. Karsten, S. Goletz, R.-C. Cheng, and Y. Cao, “Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells,” International Journal of Experimental Pathology, vol. 92, no. 2, pp. 97–105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. G. F. Springer and H. Tegtmeyer, “Origin of anti-Thomsen-Friedenreich (T) and Tn agglutinins in man and in white leghorn chicks,” British Journal of Haematology, vol. 47, no. 3, pp. 453–460, 1981. View at Publisher · View at Google Scholar · View at Scopus
  8. U. Galili, “Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody,” Springer Seminars in Immunopathology, vol. 15, pp. 155–171, 1993. View at Google Scholar
  9. G. F. Springer, “Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy,” Journal of Molecular Medicine, vol. 75, no. 8, pp. 594–602, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. O. Kurtenkov, L. Miljukhina, J. Smorodin et al., “Natural IgM and IgG antibodies to Thomsen-Friedenreich (T) antigen in serum of patients with gastric cancer and blood donors: relation to Lewis (a,b) histo-blood group phenotype,” Acta Oncologica, vol. 38, no. 7, pp. 939–943, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. O. Kurtenkov, K. Klaamas, S. von Mensdorff-Pouilly, L. Shljapnikova, and V. Chuzmarov, “Humoral immune response to MUC1 and tumor-related glycotopes (Gal beta1-3GalNAc, Gal alpha1-3Gal) in patients with gastric cancer and benign gastric diseases: relation to survival,” Acta Oncologica, vol. 46, pp. 316–323, 2007. View at Google Scholar
  12. H. H. Wandall, O. Blixt, M. A. Tarp et al., “Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes,” Cancer Research, vol. 70, no. 4, pp. 1306–1313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Smorodin, B. Sergeyev, K. Klaamas, V. Chuzmarov, and O. Kurtenkov, “The relation of the level of serum anti-TF, -Tn and -alpha-gal IgG to survival in gastrointestinal cancer patients,” International Journal of Medical Sciences, vol. 10, no. 12, pp. 1674–1682, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. V. V. Glinsky, G. Kiriakova, O. V. Glinskii et al., “Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo,” Neoplasia, vol. 11, no. 9, pp. 901–909, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. O. V. Glinskii, F. Li, L. S. Wilson et al., “Endothelial integrin α3β1 stabilizes carbohydrate-mediated tumor/endothelial cell adhesion and induces macromolecular signaling complex formation at the endothelial cell membrane,” Oncotarget, vol. 5, no. 5, pp. 1382–1389, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Almogren, J. Abdullah, K. Ghapure, K. Ferguson, V. V. Glinsky, and K. Rittenhouse-Olson, “Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy,” Frontiers in Bioscience—Scholar, vol. 4, no. 3, pp. 840–863, 2012. View at Google Scholar · View at Scopus
  17. J. P. Bouvet, D. Stahl, S. Rose, C. P. Quan, M. D. Kazatchkine, and S. V. Kaveri, “Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents,” Journal of Autoimmunity, vol. 16, no. 2, pp. 163–172, 2001. View at Google Scholar
  18. M. Abu-Shakra and Y. Shoenfeld, “Natural hidden autoantibodies,” The Israel Medicine Association Journal, vol. 10, pp. 748–749, 2007. View at Google Scholar
  19. O. Kurtenkov, J. Izotova, K. Klaamas, and B. Sergeyev, “Increased sialylation of anti-thomsen-friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential,” BioMed Research International, vol. 2014, Article ID 830847, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. O. Kurtenkov and K. Klaamas, “Increased Avidity of the Sambucus nigra Lectin-Reactive Antibodies to the Thomsen-Friedenreich Antigen as a Potential Biomarker for Gastric Cancer,” Disease Markers, vol. 2015, Article ID 761908, 8 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Kodar, J. Izotova, K. Klaamas, B. Sergeyev, L. Järvekülg, and O. Kurtenkov, “Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients,” World Journal of Gastroenterology, vol. 19, no. 23, pp. 3573–3582, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. K. A. Gustaw, M. R. Garrett, H.-G. Lee et al., “Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis,” Journal of Neurochemistry, vol. 106, no. 3, pp. 1350–1356, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Wymann, M. Ghielmetti, A. Schaub et al., “Monomerization of dimeric IgG of intravenous immunoglobulin (IVIg) increases the antibody reactivity against intracellular antigens,” Molecular Immunology, vol. 45, no. 9, pp. 2621–2628, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. N. M. Mihaylova, J. D. Dimitrov, I. K. Djoumerska-Alexieva, and T. L. Vassilev, “Inflammation-induced enhancement of IgG immunoreactivity,” Inflammation Research, vol. 57, no. 1, pp. 1–3, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. J. D. Dimitrov, C. Planchais, L. T. Roumenina, T. L. Vassilev, S. V. Kaveri, and S. Lacroix-Desmazes, “Antibody polyreactivity in health and disease: statu variabilis,” Journal of Immunology, vol. 191, no. 3, pp. 993–999, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. N. Arnold, M. R. Wormald, R. B. Sim, P. M. Rudd, and R. A. Dwek, “The impact of glycosylation on the biological function and structure of human immunoglobulins,” Annual Review of Immunology, vol. 25, pp. 21–50, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. J. M. Hayes, E. F. Cosgrave, W. B. Struwe et al., “Glycosylation and Fc receptors,” in Fc Receptors, vol. 382 of Current Topics in Microbiology and Immunology, pp. 165–199, Springer, 2014. View at Publisher · View at Google Scholar
  28. T. S. Raju, “Terminal sugars of Fc glycans influence antibody effector functions of IgGs,” Current Opinion in Immunology, vol. 20, no. 4, pp. 471–478, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Böhm, I. Schwab, A. Lux, and F. Nimmerjahn, “The role of sialic acid as a modulator of the anti-inflammatory activity of IgG,” Seminars in Immunopathology, vol. 34, no. 3, pp. 443–453, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Oaks, S. Taylor, and J. Shafffer, “Autoantibodies targetting tumor-associated antigens in metastatic cancer. Sialylated IgGs as candidate anti-inlfammatory antibodies,” Oncoimmunology, vol. 2, no. 6, Article ID e2481, 2013. View at Publisher · View at Google Scholar
  31. R. Jefferis, “A sugar switch for anti-inflammatory antibodies,” Nature Biotechnology, vol. 24, no. 10, pp. 1230–1231, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Käsermann and I. K. Campbell, “Will sialylation change intravenous immunoglobulin therapy in the future?” Clinical and Experimental Immunology, vol. 178, no. 1, pp. 100–102, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Käsermann, D. J. Boerema, M. Rüegsegger et al., “Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation,” PloS one, vol. 7, no. 6, p. e37243, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Wuhrer, L. Porcelijn, R. Kapur et al., “Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens,” Journal of Proteome Research, vol. 8, no. 2, pp. 450–456, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. M. H. J. Selman, S. E. de Jong, D. Soonawala et al., “Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination,” Molecular & cellular proteomics : MCP, vol. 11, no. 4, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. Ç. Gerçel-Taylor, L. B. Bazzett, and D. D. Taylor, “Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer,” Gynecologic Oncology, vol. 81, no. 1, pp. 71–76, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Bones, J. C. Byrne, N. Odonoghue et al., “Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms,” Journal of Proteome Research, vol. 10, no. 3, pp. 1246–1265, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Kodar, J. Stadlmann, K. Klaamas, B. Sergeyev, and O. Kurtenkov, “Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival,” Glycoconjugate Journal, vol. 29, no. 1, pp. 57–66, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Espy, W. Morelle, N. Kavian et al., “Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's),” Arthritis and Rheumatism, vol. 63, no. 7, pp. 2105–2115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. A. Selim, J. L. Burchette, E. V. Bowers et al., “Changes in oligosaccharide chains of autoantibodies to GRP78 expressed during progression of malignant melanoma stimulate melanoma cell growth and survival,” Melanoma Research, vol. 21, no. 4, pp. 323–334, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Kodar, O. Kurtenkov, and K. Klaamas, “The thomsen-friedenreich antigen and αgal-specific human IgG glycoforms: concanavalin a reactivity and relation to survival of cancer patients,” Immunological Investigations, vol. 38, no. 8, pp. 704–717, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. K. A. Luhrs, D. A. Harris, S. Summers, and M. H. Parseghian, “Evicting hitchhiker antigens from purified antibodies,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 877, no. 14-15, pp. 1543–1552, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. M. H. Parseghian, “Hitchhiker antigens: inconsistent ChIP results, questionable immunohistology data, and poor antibody performance may have a common factor,” Biochemistry and Cell Biology, vol. 91, no. 6, pp. 378–394, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. M. M. Gourevitch, S. Von Mensdorff-Pouilly, S. V. Litvinov et al., “Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients,” British Journal of Cancer, vol. 72, no. 4, pp. 934–938, 1995. View at Publisher · View at Google Scholar · View at Scopus
  45. M. E. Rabassa, M. V. Croce, A. Pereyra, and A. Segal-Eiras, “MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis,” BMC Cancer, vol. 6, article 253, 2006. View at Google Scholar
  46. U. Galili, I. Flechner, A. Knyszynski, D. Danon, and E. A. Rachmilewitz, “The natural anti-α-galactosyl IgG on human normal senescent red blood cells,” British Journal of Haematology, vol. 62, no. 2, pp. 317–324, 1986. View at Publisher · View at Google Scholar · View at Scopus
  47. H. U. Lutz and A. Bogdanova, “Mechanisms tagging senescent red blood cells for clearance in healthy humans,” Frontiers in Physiology, vol. 4, article 387, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Kaneko, F. Nimmerjahn, and J. V. Ravetch, “Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation,” Science, vol. 313, no. 5787, pp. 670–673, 2006. View at Publisher · View at Google Scholar · View at Scopus